![Man ultramarathon runner in the mountains he trains at sunset](https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png)
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Cell Dev. Biol. , 25 August 2022
Sec. Epigenomics and Epigenetics
Volume 10 - 2022 | https://doi.org/10.3389/fcell.2022.1009752
This article is part of the Research Topic Crosstalk between Epigenetics on the Development of Cancer and Cardiovascular Disease View all 6 articles
A correction has been applied to this article in:
Corrigendum: Comprehensive pan-cancer analysis of the prognostic and immunological roles of the METTL3/lncRNA-SNHG1/miRNA-140-3p/UBE2C axis
A Corrigendum on
Comprehensive pan-cancer analysis of the prognostic and immunological roles of the METTL3/lncRNA-SNHG1/miRNA-140-3p/UBE2C axis
by Jiang, X., Yuan, Y., Tang, L., Wang, J., Liu, Q., Zou, X., and Duan, L. (2021). Front. Cell Dev. Biol. 9:765772. doi: 10.3389/fcell.2021.765772
In the original article there was a mistake in the author affiliations for Xiulin Jiang which was erroneously presented as “Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, China”, it should instead be “Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences & Yunnan Province, Kunming Institute of Zoology, Kunming, China”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: m6A modification, SNHG1, miRNA-140-3p, UBE2C, pan-cancer, prognosis, immune cell infiltration, drug sensitivity
Citation: Jiang X, Yuan Y, Tang L, Wang J, Liu Q, Zou X and Duan L (2022) Corrigendum: Comprehensive pan-cancer analysis of the prognostic and immunological roles of METTL3/lncRNA-SNHG1/miRNA-140-3p/UBE2C axis. Front. Cell Dev. Biol. 10:1009752. doi: 10.3389/fcell.2022.1009752
Received: 02 August 2022; Accepted: 03 August 2022;
Published: 25 August 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Jiang, Yuan, Tang, Wang, Liu, Zou and Duan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lincan Duan, ZHVhbm11bXVodW9zYW5AMTYzLmNvbQ==
†These authors have contributed equally to this work
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.